Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Gilead

Declines in HCV franchise impact FY16 results

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead

4Q Revenues:$7.3 billion (-14%)

4Q Earnings:$3.1 billion (-34%)

FY Revenues:$30.4 billion (-7%)

FY Earnings:$13.5 billion (-25%)

Comments: Harvoni sales were down 34% to $9.1 billion for the year, and Solvaldi sales were $4.0 billion, down 10% due to lower sales and competition, partially offset by sales of Epclusa (sofosbuvir and velpatasvir), which was launched in 2016, with sales of $1.8 billion for the year. Truvada sales were $3.6 billion, up 3%. Atripla sales were $2.6 billion, down 17%. Stribild sales were $1.9 billion, down 5%. Newly launched Genvoya, a 4-in-1 HIV regimen, had sales of $1.5 billion.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters